Microglia-Neuron Interactions in a Mouse model of Low Grade Neuroepithelial Tumors by Hanna, Veolette
University of Connecticut 
OpenCommons@UConn 
Honors Scholar Theses Honors Scholar Program 
Spring 5-1-2020 
Microglia-Neuron Interactions in a Mouse model of Low Grade 
Neuroepithelial Tumors 
Veolette Hanna 
veolette.hanna@uconn.edu 
Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses 
 Part of the Animal Experimentation and Research Commons, Biology Commons, Cancer Biology 
Commons, Cell Biology Commons, Cellular and Molecular Physiology Commons, Developmental Biology 
Commons, Laboratory and Basic Science Research Commons, and the Neuroscience and Neurobiology 
Commons 
Recommended Citation 
Hanna, Veolette, "Microglia-Neuron Interactions in a Mouse model of Low Grade Neuroepithelial Tumors" 
(2020). Honors Scholar Theses. 672. 
https://opencommons.uconn.edu/srhonors_theses/672 
	
	
	
	
	
	
	
	
	
	
	
	
Microglia-Neuron	Interactions	in	a	Mouse	model	of		
Low	Grade	Neuroepithelial	Tumors	Veolette	Hanna		Thesis	Supervisor:	Professor	Joseph	Loturco	Honors	Advisor:	Professor	Randall	Walikonis																							
Abstract		 	Microglia	are	the	macrophages	of	the	brain	and	spinal	cord,	playing	an	important	role	in	the	immune	response	to	disease	states	of	the	nervous	system.	This	study	conducts	an	investigation	on	the	activity	of	microglia	in	response	to	low	grade	neuroepithelial	tumors.	Using	mouse	models	and	microglial	markers,	a	qualitative	and	quantitative	analysis	of	microglia	activation,	migration,	and	invasion	within	the	brain	cortex	during	early	stages	of	tumor	development	was	conducted.	It	was	found	that	the	presence	of	a	low	grade	neuroepithelial	tumor	in	the	cortex	of	one	hemisphere	of	the	brain	causes	significant	microglia	activation	in	comparison	to	the	cortical	tissue	of	the	healthy	hemisphere	of	that	same	brain.	However,	the	density	of	the	microglia,	indicating	their	migration	and	proliferation,	did	not	significantly	differ	between	the	two	hemispheres.	Analysis	of	microglia	interactions	with	neurons	was	also	conducted	to	determine	the	implications	of	increased	microglia	activation	surrounding	the	low	grade	neuroepithelial	tumor.	Synaptic	engulfment	could	be	the	cause	of	the	epileptogenicity	typically	associated	with	these	tumors.	We	found	that	the	density	of	microglia	wrapping	around	neurons	does	not	increase	significantly	in	the	region	of	tumor	growth,	however,	more	studies	will	need	to	be	conducted	to	quantify	synaptic	connections	in	the	region.		
Introduction		Cancers	of	the	Central	Nervous	System	(CNS)	are	the	second	most	prevalent	group	of	cancers	in	children,	after	leukemia,	and	the	leading	cause	of	cancer-related	death	in	children	and	adolescents	aged	20	years	and	under1.	CNS	tumors	are	associated	with	a	high	mortality	rate,	and	about	90%	of	survivors	are	left	with	long-term	morbidities	and	deficits2.	These	include	pituitary	dysfunction,	growth	hormone	deficiency,	epilepsy,	vision	loss,	impaired	motor	skills,	memory	dysfunction,	attention	and	behavioral	disorders	and	reduced	intelligence	quotient	(IQ)1.		Pediatric	low-grade	gliomas	(PLGGs)	are	the	most	common	brain	tumors	in	children	and	adolescents3.	In	pediatric	low-grade	gliomas,	the	analysis	of	the	molecular	and	genetic	mechanisms	underlying	tumor	growth	showed	that	activation	of	the	
MAPK/ERK	(mitogen	activated	protein	kinase/extracellular	signal-related	kinase)	pathway	is	fundamental	for	their	development1.	This	pathway	normally	functions	as	signal	transduction	between	extracellular	growth	factor	stimuli	and	gene	transcription	to	initiate	normal	cell	division	and	differentiation4.	Excessive	cell	proliferation	can	occur	when	the	ERK	pathway	is	activated	without	the	binding	of	extracellular	growth	factor.	This	can	happen	when	there	are	alterations	in	the	BRAF	(v-raf	murine	sarcoma	viral	oncogene	homolog	B1)	gene	(Figure	1).			
		
Figure	1.	Diagram	showing	the	RAS-RAF	pathway,	and	the	effects	of	mutated	BRAF	on	cell	proliferation	and	survival.	Adapted	from	Maraka	et.	al.4	GF:	Growth	Factors;	RTK:	Receptor	Tyrosine	Kinase;	P:	Phosphate.	Activation	of	RAS	by	extracellular	growth	factors	leads	to	normal	cell	proliferation	and	survival.	When	BRAF	is	mutated,	the	MEK	pathway	is	activated	without	growth	factor	signaling.			The	BRAF	gene	is	located	at	chromosome	7	(7q34)	and	encodes	BRAF	protein,	a	member	of	the	RAF	family	of	serine/threonine	kinases	that	participates	in	the	cascade	of	the	Ras-Raf-MEK-ERK	pathway	or	the	MAPK/ERK	signaling	pathway.		The	majority	of	BRAF	mutations	affect	amino	acid	residues	located	within	the	exon	11	and	15	kinase	domains,	which	stabilize	the	kinase	in	its	inactive	form4.	BRAF	mutations	in	these	locations	cause	increased	BRAF	kinase	activity,	keeping	the	ERK	pathway	activated5.	The	BRAF-V600E	mutation	(Figure	1),	the	most	common	BRAF	mutation	in	human	cancers,	is	a	missense	mutation	located	in	exon	15,	nucleotide	1799,	in	which	valine	substitutes	glutamic	acid	at	codon	600	(V600E)6,7.	Over	90%	of	BRAF	mutations	in	pediatric	gliomas	are	BRAFV600E	mutations1.			
The	pathological	spectrum	of	PLGGs	includes	gangliogliomas,	dysembryoplastic	neuroepithelial	tumors	(DNETs),	diffuse	astrocytomas,	and	pilocytic	astrocytomas,	the	most	common	pediatric	brain	tumor3.	Epilepsy,	irregular	synaptic	firing,	is	a	common	phenotype	of	patients	that	have	brain	cancer	caused	by	the	BRAFV600E	mutation.	Low-grade	neuroepithelial	tumors	(LGNTs)	are	CNS	tumors	presenting	in	children	and	young	adults,	often	with	a	history	of	epilepsy8.	LGNTs	include	the	pilocytic	astrocytoma,	as	well	as	more	uncommon	tumors	such	as	the	ganglioglioma,	dysembryoplastic	neuroepithelial	tumor	(DNET),	and	angiocentric	glioma,	which	are	associated	with	chronic	epilepsy	and	are	referred	to	as	‘long-term	epilepsy-associated	tumors’	(LEATs)9,10. Usually,	LEAT	are	characterized	by	slow	growth,	young	onset	of	epilepsy	as	the	primary	neurological	symptom,	and	a	location	in	the	temporal	lobe11.	Gangliogliomas	(GG)	are	an	increasingly	recognized	cause	of	epilepsy	and	represent	the	most	common	type	of	LEAT	in	young	patients	undergoing	surgery	for	chronic	intractable	focal	epilepsy10,12,13.	Gangliogliomas	account	for	2–5%	of	all	brain	tumors,	elicit	early-onset	uncontrolled	epileptic	seizures	in	children14	and	consist	of	mutated	glia	and	neurons.	A	recent	study	revealed	that	expression	of	BRAFV600E	is	associated	with	a	worse	postoperative	seizure	outcome	in	glioneuronal	tumors,	and	this	could	be	due	to	lack	of	removal	of	focal	cortical	dysplasia	(FCD)	in	the	adjacent	cortex11,15.	BRAF	mutations	have	been	identified	in	up	to	50%	of	gangliogliomas	as	well	as	the	associated	FCD11.	Several	studies	have	suggested	that	intrinsic	factors	in	ganglioglioma	may	contribute	to	their	epileptogenicity14.	By	impairing	GABAergic	inhibition,	the	downregulation	of	GABA	receptor	subunits	in	gangliogliomas	has	been	implicated	in	tumor	epileptogenicity,	but	its	molecular	basis	remains	unclear15,16.		 Recent	studies	have	found	that	the	activation	of	microglia,	the	tissue	resident	immune	cells	of	the	central	nervous	system,	play	a	role	in	sculpting	synaptic	connections18.	Microglia	are	active	surveyors	of	the	extracellular	environment19	in	the	brain,	and	have	been	implicated	in	important	developmental,	homeostatic,	and	disease	processes20.	When	the	CNS	is	harmed	by	acute	insults	and	chronic	disease	states,	activation	of	microglia	results	in	morphological	changes	such	as	enlargement	of	their	cell	bodies	and	asymmetrical	distribution	of	their	processes,	as	well	as	the	increased	expression	of	activation	molecules21.	Whether	microglia	activation	is	protective	or	destructive	to	the	CNS	remains	controversial22,	and	this	study	seeks	to	address	that	question.		Excitatory	synapses	are	phagocytized	and	eliminated	by	microglia	during	development	and	pruning.	Inhibitory	synapses	are	also	displaced	by	microglia	as	a	neuroprotective	response	to	injury.	Less	GABAergic	activity	increases	the	firing	of	synaptic	NMDARs,	which	induces	phosphorylation	of	the	transcription	factor	CREB	(cAMP	responses	element	binding	protein)	and	de	novo	transcription	of	genes	that	
promote	neuronal	survival23,24.	While	this	may	protect	the	brain	from	subsequent	injury,	this	kind	of	mechanism	can	be	aiding	the	survival	of	brain	tumors,	making	it	harmful	and	not	protective.	In	addition,	the	interaction	of	microglia	with	neuronal	circuits	could	be	the	cause	of	the	epileptic	activity	in	LGNTs	and	LEATs,	but	this	has	not	been	studied	previously.	Microglia	activation	and	synaptic	engulfment	could	be	the	molecular	basis	for	the	impaired	inhibition	found	in	these	tumors,	responsible	for	epileptic	seizures.		With	this	knowledge,	I	hypothesized	that	microglia	activation	in	BRAFV600E	glial	tumors	causes	the	circuit	remodeling	responsible	for	epileptic	symptoms.	In	this	study,	we	used	mice	to	model	the	phenotype	of	a	low-grade	neuroepithelial	tumor.	These	mice	have	brains	with	a	small	fraction	of	neurons	and	astrocytes	expressing	BRAFV600E	mutant	protein,	transfected	via	in	utero	electroporation	(IUE).	By	using	immunohistochemistry,	I	compared	the	number	and	activation	level	of	microglia	as	well	as	the	number	of	microglia	interacting	with	neurons	in	the	transfected	hemisphere,	which	harbors	the	mutant	neurons	and	glia,	and	in	the	non-transfected	control.	Interactions	of	activated	microglia	with	transfected	and	non-transfected	neurons	in	the	tumor	region	and	healthy	region	of	the	mouse	brains	could	also	be	analyzed.	I	found	that	microglia	residing	in	the	region	of	tumor	growth	increase	in	activation,	but	their	number	does	not	increase.	I	also	found	that	the	quantity	of	neuronal	cell	bodies	in	contact	with	microglia	does	not	change	significantly	between	the	BRAFV600E	expressing	region	and	the	control	region	of	the	mouse	brains.			
Materials	and	Methods		Our	approach	to	creating	an	animal	model	of	the	LGNT	condition	was	to	introduce	a	mutated	oncogenic	BRAF	gene	into	radial	glia	cells	in	embryonic	mouse	brain	using	
in-utero	electroporation.	The	BRAFV600E	mutation	was	delivered	to	the	radial	glia	cells	in	the	brains	of	the	mice	between	embryonic	day	13	to	16	(Figure	2).		
		
Figure	2.	Diagram	showing	the	time	window	of	neurogenesis	and	gliogenesis	from	radial	glia	cells	in	mouse	embryo	brain.	Adapted	from	Mitrousis,	et.	al.25	nIPCs:	neurogenic	intermediate	progenitor	cell;	E:	embryonic	day.	Radial	glia	(RG)	cells	have	been	shown	to	generate	multiple	cell	types	during	cortical	development25.	RG	cells	initially	undergo	symmetric	divisions	that	produce	additional	RG	cells	and	expand	the	proliferative	population	in	the	ventricular	zone26.		RG	cells	divide	in	the	ventricular	zone	to	produce	intermediate	progenitor	cells,	and	intermediate	progenitor	cells	divide	in	the	subventricular	zone	to	produce	pairs	of	daughter	neurons26.	RG	cells	also	detach	from	the	ventricle	and	translocate	toward	the	pial	surface	toward	the	end	of	development,	and	their	division	generates	the	population	of	astrocytes	located	in	the	cerebral	cortex26.	GLAST	and	NESTIN	promoters	were	used	to	drive	piggybac	transposase	expression,	which	inserted	the	BRAFV600E	coding	sequence	into	neural	progenitor	genomes27.	NESTIN	promoter	drove	the	expression	of	the	mutant	protein	in	radial	glia	cells	that	produce	neurons	exclusively.	GLAST	promoter	drove	the	mutation	to	be	expressed	in	radial	glia	cells	that	give	rise	to	neurons	as	well	as	those	that	give	rise	to	astrocytes	(Figure	3).	These	two	conditions	were	created	to	see	if	different	cell	types	carrying	the	mutation	trigger	different	responses	in	microglia.			
		
Figure	3.	Illustration	showing	the	vectors	designed	to	overexpress	BRAFV600E	in	a	
piggybac	system,	to	be	delivered	to	embryonic	mice	brains	with	IUE.	The	PBase	expressing	vector	encodes	the	enzyme	that	will	insert	the	recombinant	gene	into	the	genome	for	stable	transfection.	The	eGFP	expressing	vector	is	used	to	label	the	transfected	cells.		The	mice	were	perfused	with	4%	PFA	and	the	dissected	brains	were	left	in	the	same	fixative	overnight	to	complete	the	fixation	of	the	entire	tissue.	The	brain	tissue	was	then	sectioned	with	a	Leica	vibratome	at	60	µm	thickness.	We	used	indirect	immunohistochemistry	to	tag	Iba-1	protein,	an	indicator	of	microglia	activation,	and	GFP	protein,	an	indicator	of	transfected	neurons	and	astrocytes	(Figure	4),	with	antibodies.	The	primary	antibodies	consisted	of	rabbit	anti-mouse	Iba-1	(1:1000	dilution	in	1xPBS+0.5%	Triton	X-100+0.5%	normal	goat	serum,	cat	#	ab178846,	Abcam)	and	chicken	anti-mouse	GFP	(1:1000	dilution	in	1xPBS+0.5%	Triton	X-100+0.5%	normal	goat	serum,	cat	#	GFP-1010,	AVES	Labs).	The	primary	antibody	treatment	was	carried	out	for	48	hours	at	4°C.	The	secondary	antibodies	consisted	of	goat	anti-rabbit	Alexa	568	(Red)	or	Alexa	647	(Far	Red)	and	goat	anti-chicken	Alexa	488	(Green).	The	secondary	antibodies	were	used	on	tissue	in	1:1000	dilution	in	1XPBS+0.2%	Triton	X-100+0.5%	normal	goat	serum	at	room	temperature	for	2	hours.	The	tissue	sections	were	washed	with	1XPBS+0.2%	Triton	X-100+0.5%	normal	goat	serum	3x	20	min	at	room	temperature	between	the	primary	antibody	and	secondary	antibody	incubations,	and	between	the	secondary	antibody	incubation	and	mounting.	Imaging	acquisition	parameters	consisted	of	laser	lines	at	568	nm	and	488	nm,	on	a	Keyence	BZ-X700	Microscope	or	Zeiss	SP8	Confocal	Microscope	at	the	UConn	Microscopy	Core	Facility.	During	imaging,	the	channels	were	pseudo-colored	to	Magenta	or	Cyan	for	microglia,	and	Green	for	transfected	neurons	and	astrocytes.	Post-image	processing	involved	ImageJ	for	overlay,	cell	
counting,	and	signal	intensity	maps.	Microsoft	Excel	was	used	to	store	quantitative	data	and	calculate	microglia	density	in	the	tissue.				
	
Figure	4.	Diagram	of	the	methods	and	materials	used	for	our	experiments.			The	COUNTER	Plug-In	in	ImageJ	was	used	to	quantify	microglia	in	transfected	and	non-transfected	tissue.	The	3D	surface	plot	function	in	ImageJ	was	used	to	quantify	fluorescent	signal	intensity.			In	the	following	experiments,	Parvalbumin	interneurons	were	also	marked	in	order	to	analyze	microglia	interactions	with	inhibitory	neuron	cell	bodies.	The	Parvalbumin	neurons	were	identified	with	endogenous	expression	of	red	fluorescent	protein,	TdTomato	in	a	transgenic	mouse	line	(PV-Cre:Ai14).	Pyramidal	neurons	transfected	with	GLAST_BRAFV600E	or	NESTIN_BRAFV600E	were	identified	again	with	anti-GFP	primary	antibody	and	Alexa	488	fluorescent	protein.	Microglia	were	marked	again	with	Iba-1	immunohistochemistry	and	a	far-red	secondary	antibody	that	was	pseudo-colored	to	cyan	during	image	acquisition	and	analysis.		
	
	
	
	
	
Results		
Microglia	are	activated	in	regions	of	glia	transformed	with	BRAFV600E.		When	mouse	radial	glia	cells	expressed	the	BRAFV600E	mutation	under	the	control	of	GLAST	promoter,	a	glioneuronal	tumor	developed.	When	mouse	radial	glia	cells	expressed	the	BRAFV600E	mutation	under	the	control	of	NESTIN	promoter,	mostly	neurons	were	transfected	(Figure	5).	Immunohistochemistry	experiments	and	fluorescent	imaging	comparing	tissue	transformed	with	GLAST_BRAFV600E	and	NESTIN_BRAFV600E	showed	that	microglia	activation	increased	when	astrocytes	expressed	BRAFV600E.	Specifically,	microglia	marked	with	antibodies	for	the	Iba-1	protein,	an	indicator	of	activation,	demonstrated	brighter	fluorescent	signals	in	the	mouse	brain	containing	glia	transfected	with	BRAFV600E,	but	not	in	brains	that	only	contain	neurons	transfected	with	BRAFV600E	(Figure	5,6).	To	determine	the	origins	of	this	qualitative	difference	observed	in	initial	images,	two	quantification	methods	were	used.	First,	we	quantified	the	density	of	microglia	in	the	transfected	region	and	compared	with	the	healthy	hemisphere	as	a	control	(Figure	6).	Second,	we	quantified	the	signal	intensity	of	microglia	in	the	tumor	region	and	compared	with	the	healthy	hemisphere	as	a	control	(Figure	7).			The	density	of	microglia	did	not	differ	significantly	between	the	transfected	and	non-transfected	hemispheres	(Figure	6B).	Thus,	quantification	of	microglia	density	in	4	different	mice	brains	transfected	with	the	BRAFV600E	mutation	under	control	of	GLAST	promoter	showed	that	the	initial	observation	of	increased	Iba-1	signal	intensity	in	the	transfected	hemisphere	could	not	be	attributed	to	an	increase	in	microglia	number.	Therefore,	proliferation	or	migration	towards	the	transfected	region	was	not	evident.	This	was	confirmed	through	the	imaging	of	3D	surface	plots	in	ImageJ	(Figure	7).			In	mouse	brain	tissue	with	NESTIN_BRAFV600E	transfection,	we	did	not	see	a	difference	in	Iba-1	signal	intensity	between	the	transfected	and	control	hemisphere.		This	indicates	that	mutated	astrocytes	have	an	impact	on	microglia	activity,	but	the	underlying	mechanism	causing	this	phenotype	is	not	known.		
Activated	microglia	do	not	wrap	around	more	neuron	cell	bodies	in	regions	of	
glia	transformed	with	BRAFV600E	compared	to	the	control.	Previous	reports	showed	that	activated	microglia	can	have	increased	interaction	with	neurons	soma18.	Therefore,	I	wanted	to	investigate	whether	the	activated	microglia	in	GLAST_BRAFV600E	transfected	brain	region	have	an	increased	tendency	to	wrap	around	the	soma	of	nearby	neurons.	To	examine	the	microglia-neuron	soma	interaction,	I	quantified	the	number	of	microglia	in	close	contact	with	pyramidal	neurons	or	inhibitory	neurons	(Parvalbumin	positive)	in	transfected	versus	nontransfected	hemispheres.	Parvalbumin	positive	inhibitory	interneurons	express	TdTomato,	giving	them	a	red	fluorescent	signal	(Figure	8).	Mutated	excitatory	neurons	continued	to	be	marked	by	GFP	signal.	I	used	Alexa-647	conjugated	secondary	antibody	for	Iba-1	antibody	to	
differentiate	the	microglia	in	the	tissue.	40x	magnification	images	from	3	different	brains	were	taken	on	the	Confocal	microscope,	and	the	number	of	microglia	interacting	with	neuron	soma	were	counted	(Figure	9).	The	wrapping	of	neuron	soma	by	microglia	could	indicate	the	displacement	of	synapses	on	the	soma	(which	are	primarily	inhibitory),	or	the	engulfment	of	neurons	for	phagocytosis.	Our	analysis	showed	that	the	amount	of	microglia-neuron	contacts	did	not	change	between	the	transfected	and	non-transfected	hemispheres.	This	indicates	that	the	activation	of	microglia	in	regions	of	glia	transformed	with	BRAFV600E	does	not	necessarily	entail	increased	microglia-neuron	interactions	in	the	form	of	microglia	wrapping	around	neuron	cell	bodies.								 															
Figure	5.	Fluorescent	images	of	mouse	brain	sections	expressing	BRAFV600E	under	the	control	of	NESTIN	(A-C)	or	GLAST	(D-F)	promoter.	The	transfection	was	confirmed	with	EGFP	signal	(A,	D).	Iba-1	labels	microglia	(B,	E),	and	both	stains	are	observed	with	an	overlay	(C,	F).	After	immunohistochemistry,	the	tissue	sections	were	imaged	at	4x	magnification	and	the	signal	difference	between	transfected	and	non-transfected	hemispheres	was	analyzed.	Iba-1	signal	intensity,	showing	microglia	activation,	is	higher	on	the	transfected	side	of	GLAST_BRAFV600E	tissue	sections	(Box	in	F).	Scale	bars:	200	µm.							
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Figure	6.	(A)	Fluorescent	microscope	images	of	mouse	brain	sections	at	20x	magnification.	EGFP	(a,	d)	indicates	transfected	astrocytes	and	neurons.	Iba-1	(b,	e)	immunohistochemistry	indicates	microglia.	Brighter	Iba-1	signal	intensity	indicates	increased	microglia	activation	in	the	transfected	hemisphere	in	comparison	to	the	control,	non-transfected	hemisphere.	(c,	f)	Scale	bars:	50	µm.	The	bar	graph	in	(B)	shows	the	average	density	of	microglia	(number	of	cells/mm3)	across	the	cortex	of	mice	brains	transfected	with	GLAST_BRAFV600E.	V600E:	number	of	microglia	in	the	transfected	hemisphere;	CTRL:	number	of	microglia	in	the	nontransfected	hemisphere.	30	20x	magnification	images	of	transfected	tissue	and	27	20x	magnification	images	of	non-transfected	tissue	in	4	mice	brains	was	analyzed,	and	the	density	of	microglia	on	the	transfected	and	non-transfected	side	of	each	brain	was	calculated.	A	2	tail	T-test	was	calculated	for	the	p-value.	Even	though	the	average	density	of	microglia	in	the	cortex	increased	on	the	transfected	side	of	the	brain,	this	difference	in	microglia	number	was	not	found	to	be	significant	(p>0.05).			
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Figure	7.	(A)	A	3D	surface	plot	for	the	transfected	side	of	the	brain	indicates	more	microglia	activation	with	higher	fluorescent	signal	intensity	compared	to	the	3D	surface	plot	in	(B)	of	the	non-transfected	side	of	the	brain.	(C)	Signal	intensity	quantification	showed	a	significant	increase	in	Iba-1	signal	in	BRAFV600E	transfected	tissue	(p<0.01)	under	control	of	GLAST	promoter.	This	indicates	a	correlation	between	astrocyte	expression	of	BRAFV600E	and	microglia	activation.		
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Figure	8.	Immunofluorescence	images	at	40x	magnification	on	a	confocal	microscope	marking	different	cell	types.	Arrows	show	microglia	(cyan),	inhibitory	interneurons	(red),	and	transfected	pyramidal	excitatory	neurons	(green)	in	mouse	cortical	tissue.	Scale	bar:	30	µm		 	
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Figure	9.	(A)	Wrapping	of	microglia	(cyan)	around	the	soma	of	a	pyramidal	neuron	(green)	transfected	with	BRAFV600E	under	control	of	GLAST	promoter	and	marked	with	GFP.	(B)	Microglia	(cyan)	in	contact	with	the	soma	of	a	Parvalbumin	inhibitory	interneuron	expressing	TdTomato	(red).	Scale	bars:	10	µm.	Bar	graphs	show	the	density	of	microglia	(number	of	cells/mm3)	wrapping	neurons	in	transfected	(V600E)	and	non-transfected	(CTRL)	tissue.	(C)	There	was	no	significant	difference	between	the	numbers	of	microglia	contacts	with	neurons	in	the	tumor	region	and	control	region.	(p	>	0.05)	(D)	The	percent	of	transfected	neurons,	interneurons,	and	non-transfected	neurons	wrapped	by	microglia	is	compared.	BRAFV600E	expressing	excitatory	neurons	have	the	most	contact	with	microglia,	while	inhibitory	interneurons	in	the	non-transfected	hemisphere	have	the	least	contact	with	microglia.	However,	these	differences	were	not	found	to	be	significant	(p>0.05).		
Discussion		The	activation	of	microglia	in	mouse	cortex	BRAFV600E	in	developing	LGNTs	has	been	shown	to	be	dependent	on	the	expression	of	BRAFV600E	in	astrocytes.	Astrocyte	signaling	to	microglia	could	be	essential	for	microglia	to	become	active	in	the	tumor	region.			A	recent	study	has	found	that	Interleukin-33,	a	cytokine	released	by	synapse-associated	astrocytes,	is	required	for	synaptic	development	in	the	thalamus	and	spinal	cord,	and	signals	to	microglia	to	promote	increased	synaptic	engulfment28.	Interleukin-33	(IL-33)	is	released	from	nuclear	stores	following	tissue	damage,	including	spinal	cord	injury,	stroke,	and	Alzheimer’s	disease28.	Similar	signaling	may	occur	following	tissue	damage	caused	by	LGNTs,	but	further	studies	must	be	conducted.	A	future	direction	of	this	project	could	be	to	quantify	the	release	of	cytokines	from	astrocytes	in	these	mice	brains,	and	the	effects	of	these	signals	on	microglia	activity.		Synaptic	engulfment	by	microglia	could	be	linked	to	increased	tumor	survival	and	epileptic	activity	in	LGNTs.	However,	in	this	study,	we	did	not	find	that	the	activation	of	microglia	in	regions	of	glia	transformed	with	BRAFV600E	came	with	an	increase	in	microglia	contacts	with	neurons	in	these	regions.	More	experiments	should	be	conducted	to	confirm	this	result.	An	EGFP-only	expressing	mouse	line	should	be	used	as	a	control	to	compare	with	the	number	of	microglia	wrapping	transfected	neurons	(Figure	9D).	Increasing	the	sample	size	from	3	brains	to	5	brains	for	more	accurate	cell	counting	should	be	done.	Then,	we	will	be	able	to	compare	the	wrapping	of	microglia	around	excitatory	neurons	and	inhibitory	interneurons	in	transfected	and	control	tissue.			After	investigating	activated	microglia	interactions	with	neurons	through	cell	body	contacts,	we	can	conduct	more	detailed	studies.	Future	studies	must	be	done	quantifying	the	neuron	cell	body	circumference	in	contact	with	microglia,	and	this	
quantification	could	possibly	show	a	more	significant	result.	We	know	how	many	neurons	are	wrapped	by	microglia	in	these	brains,	but	we	did	not	quantify	the	amount	of	space	on	each	cell	soma	is	covered.	By	(1)	Quantifying	the	percent	of	neuron	cell	body	circumference	occupied	by	microglia	and	(2)	marking	GABAergic	inhibitory	synapses	with	immunofluorescence,	we	could	determine	the	specific	amount	of	synaptic	transmission	blocked	by	activated	microglia	in	the	tumor	region.	Conducting	this	quantification	would	increase	our	understanding	of	the	affects	of	microglia	activation	on	brain	circuitry	within	LGNTs.			
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